Press Releases
iCAD to Participate in the LD Micro Main Event XVII
NASHUA, N.H. – October 16, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October…
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
NASHUA, N.H., PARIS, FRANCE, October 3, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France….
iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024
NASHUA, N.H. – September 11, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference…
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
NASHUA, N.H. – August 13, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months…
iCAD to Report Second Quarter 2024 Financial Results on August 13, 2024
NASHUA, N.H., August 6, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday,…
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion NASHUA, N.H., WILLIAMSVILLE, N.Y., RALEIGH, N.C., July 29, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with Windsong Radiology Group, one of US Radiology…
iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024
Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD’s Breast Health Suite of AI Solutions NASHUA, N.H., June 26, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of…
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
NASHUA, N.H. – June 4, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June…
iCAD Reports Financial Results for First Quarter Ended March 31, 2024
NASHUA, N.H. – May 15, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter…
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
UPDATE: Call Time is 8:30 AM Eastern Time NASHUA, N.H., May 2, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at…